Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose remimazolam for prevention of etomidate-induced myoclonus in elective neurointerventional surgery
ChiCTR2300079274Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam and etomidate in myoclonus (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Incidence of myoclonus and Severity of myoclonus. Started Dec 2023; status: recruiting.
02
Drugs
remimazolametomidate
03
Conditions
myoclonus
Beyond the preview
Go deeper on ChiCTR2300079274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079274.